A distinct prognostic significance in the expression of claudin-3 and mostly of claudin-4 between triple-negative and luminal breast carcinomas was identified. Specifically, in triple-negative carcinomas, claudin-4 positivity could probably be considered as a biomarker of favorable prognosis, whereas in luminal cancers with claudin-4-positive expression, the administration of targeted therapy should eventually be part of the patients' management in the near future.
Primary lung squamous cell carcinomas (SCC) form a distinct group in terms of molecular characteristics. There is no single assay that predicts outcome and selects optimal treatment for early stage SCC, especially for stage I where there is a 33-60% risk of disease-related death within 5 years after “curative” surgical treatment. The current staging system fails to select early stage SCC patients likely to recur and die of their disease after surgery. Emerging data using gene-expression profiling has shown that lung SCCs can be classified into high and low risk groups by signatures associated with down-regulation of epidermal development genes. However, the development of such molecular tools has been limited by lack of reproducibility and independent validation. Here we develop and validate a 3-protein classifier that stratifies early stage SCC by risk. Quantitative immunofluorescence (AQUA®) was employed to measure proteins known to be part of SCC gene risk signatures; Cytokeratins 5 (CK5), 8 (CK8), 13 (CK13), 14 (CK14), 15 (CK15), 16 (CK16), 17 (CK17), 18 (CK18) and 19 (CK19) were analyzed in a multivariate Cox proportional hazards regression model following stepwise selection with backward elimination resulting in a 3-protein weighted classifier. A risk score was calculated combining binarized quantitative measurements of CK13, CK14 and CK17 in a training set of 160 SCC patients. X-tile software was employed to identify the optimal cut off risk score and classify patients into high and risk groups; this cut point was applied to an independent cohort of 76 SCC patients. Weighted expression of CK13, CK14 and CK17 was used to build a model to classify patients in high and low risk groups. Survival analysis showed that patients in the low risk group had a longer median overall survival compared to the high risk group (46 vs. 28 months, log rank p=0.004). Multivariate analysis revealed an independent increased risk of death for all SCC patients with high scores (HR=1.76, 95% CI 1.28-2.5, p=0.001). Then the 3-biomarker classifier was tested on an independent cohort of 76 SCC patients which showed a 30.1 vs. 55 month median survival for high and low risk patients respectively (log rank p=0.001). Multivariate analysis in this cohort adjusting for age, gender and stage verified the significant prognostic role of the classifier (HR=1.88, 95% CI 1.22-2.9, p=0.004). The independent prognostic value of our model was especially valuable in stage I patients (HR=1.91, 95% CI 1.15-3.17, p=0.013) and even more compelling for stage I patients that were treated with surgery only (HR=2.92, 95% CI 1.31-6. 25, p=0.009). We developed and validated a quantitative biomarker-based independent prognostic model that accurately stratifies SCC patients for risk of disease specific death. Our classifier could be used to determine which stage I SCC patients can be treated with surgery alone and which would benefit from adjuvant chemotherapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4643.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.